Literature DB >> 22424193

Mixed connective tissue disease: an overview of clinical manifestations, diagnosis and treatment.

Oscar-Danilo Ortega-Hernandez1, Yehuda Shoenfeld.   

Abstract

The most common clinical manifestations of mixed connective disease are Raynaud's phenomenon, arthralgias, swollen joints, esophageal dysfunction, muscle weakness and fingers sausage-like appearance together with the presence of anti-ribonucleoprotein (RNP) antibodies. However, organ involvement is more extensive than first descriptions reported. The disease can be serious with development of pulmonary, kidney, cardiovascular, gastrointestinal and central nervous system manifestations. The worst prognosis and high mortality are associated with the presence of pulmonary disease. Although a different set of clinical criteria have been proposed, there is no consensus about the most accurate. There is no full agreement about treatment and the initial impression of a satisfactory response to low doses of steroids is not always the rule. Herein, we review available evidence to a better approach to all previous topics.
© 2012. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22424193     DOI: 10.1016/j.berh.2012.01.009

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  28 in total

1.  Can SLE classification rules be effectively applied to diagnose unclear SLE cases?

Authors:  A Mesa; M Fernandez; W Wu; G Narasimhan; E L Greidinger; D K Mills
Journal:  Lupus       Date:  2016-07-11       Impact factor: 2.911

2.  Following leads: connecting dysphagia to mixed connective tissue disease.

Authors:  Rita de Sousa Gameiro; Ana Isabel Alves Reis; Ana Cristina Grilo; Carla Noronha
Journal:  BMJ Case Rep       Date:  2018-03-05

Review 3.  Biomarkers in rheumatic diseases: how can they facilitate diagnosis and assessment of disease activity?

Authors:  Chandra Mohan; Shervin Assassi
Journal:  BMJ       Date:  2015-11-26

4.  Collapsing glomerulopathy in a patient with mixed connective tissue disease.

Authors:  Gajapathiraju Chamarthi; William L Clapp; Saraswathi Gopal
Journal:  CEN Case Rep       Date:  2020-10-14

5.  Increased levels of anti-heat-shock protein 60 (anti-Hsp60) indicate endothelial dysfunction, atherosclerosis and cardiovascular diseases in patients with mixed connective tissue disease.

Authors:  Edit Bodolay; Zoltan Prohászka; Gyorgy Paragh; Istvan Csipő; Gabor Nagy; Renata Laczik; Nora Demeter; Eva Zöld; Britt Nakken; Gyula Szegedi; Peter Szodoray
Journal:  Immunol Res       Date:  2014-10       Impact factor: 2.829

6.  Associations between circulating endostatin levels and vascular organ damage in systemic sclerosis and mixed connective tissue disease: an observational study.

Authors:  Silje Reiseter; Øyvind Molberg; Ragnar Gunnarsson; May Brit Lund; Trond Mogens Aalokken; Pål Aukrust; Thor Ueland; Torhild Garen; Cathrine Brunborg; Annika Michelsen; Aurelija Abraityte; Anna-Maria Hoffmann-Vold
Journal:  Arthritis Res Ther       Date:  2015-08-28       Impact factor: 5.156

7.  Brachial Neuritis With Phrenic Nerve Involvement in a Patient With a Possible Connective Tissue Disease.

Authors:  Meera Subash; Gaurav Patel; John Welker; Kenneth Nugent
Journal:  J Investig Med High Impact Case Rep       Date:  2014-05-09

Review 8.  Utility of immunologic testing in suspected rheumatologic disease.

Authors:  Monica Bhagat; Shiv T Sehra; Anupama Shahane; Mildred Kwan
Journal:  Curr Allergy Asthma Rep       Date:  2014-01       Impact factor: 4.919

Review 9.  Autoimmune hepatitis as a presenting manifestation of mixed connective tissue disease in a child. Case report and review of the literature.

Authors:  Katarina Sedej; Nataša Toplak; Marina Praprotnik; Boštjan Luzar; Jernej Brecelj; Tadej Avčin
Journal:  Pediatr Rheumatol Online J       Date:  2015-11-10       Impact factor: 3.054

10.  A case of subacute cutaneous lupus erythematosus in a patient with mixed connective tissue disease: successful treatment with plasmapheresis and rituximab.

Authors:  M Fantò; S Salemi; F Socciarelli; A Bartolazzi; G A Natale; I Casorelli; A Pavan; S Vaglio; R Di Rosa; R D'Amelio
Journal:  Case Rep Rheumatol       Date:  2013-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.